MedTrace Logo

A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

NCT03055611 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2024-10-02

No results posted yet for this study

Summary

Elocta (rFVIIIFc) and Alprolix (rFIXFc) are recombinant extended half-life coagulation factor products. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Elocta and Alprolix in the prophylactic treatment of haemophilia A and B.

Conditions

  • Haemophilia A
  • Haemophilia B

Interventions

DRUG

ELOCTA

Extended half-life factor VIII product

DRUG

ALPROLIX

Extended half-life factor IX product

Sponsors & Collaborators

  • Swedish Orphan Biovitrum

    lead INDUSTRY

Principal Investigators

  • Study Physician, MD · Swedish Orphan Biovitrum

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-09
Primary Completion
2022-04-19
Completion
2022-04-19

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03055611 on ClinicalTrials.gov